A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Latest Information Update: 07 Apr 2025
At a glance
- Drugs Defactinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- 02 Apr 2025 Planned End Date changed from 1 Dec 2024 to 10 Jul 2025.
- 02 Apr 2025 Planned primary completion date changed from 1 Dec 2024 to 10 Jul 2025.
- 02 Apr 2025 Status changed from recruiting to active, no longer recruiting.